β-Amyloid (Aβ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Aβ, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3β, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3β after exposure to oligomeric Aβ in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3β, even in the absence of Aβ, is sufficient to produce a phenocopy of Aβ-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3β prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3β inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3β inhibition robustly decreased the oligomeric Aβ load in the mouse brain. All these findings support the idea that GSK3β is aberrantly activated by the presence of Aβ, and contributes, at least in part, to the neuronal anatomical derangement associated with Aβ plaques in AD brains and to Aβ pathology itself.
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Background
Indisputable genetic data point to β-amyloid (Aβ) as a central player in Alzheimer's disease (AD) pathophysiology. However, how and in which way brain Aβ accrual leads to neurotoxicity and impaired cognition in AD is not completely understood and identifying the signaling pathways and mechanisms involved may prove critical to prevent or cure this illness. It has been recently proposed that glycogen synthase kinase-3 (GSK-3), a multi-tasking kinase with major roles in brain signaling, may be important in the process leading to Aβ-mediated neural system collapse and dementia in AD. "The GSK-3 hypothesis of AD" argues that overactivity of GSK-3β, the most abundant of two isoforms (GSK-3α and GSK-3β) expressed in neurons, accounts for cognitive impairment, tau hyperphosphorylation, increased Aβ production, neuronal death and neuroinflammation in AD (Hooper et al., 2008) .
Remarkable connections between GSK-3 and the hallmarks of AD have been identified. GSK-3β is a key kinase required for AD-type abnormal hyperphosphorylation of tau (Kosik, 1992) and GSK-3β overexpression results in tau hyperphosphorylation and microtubule disruption in mice (Lucas et al., 2001) . Aβ activates GSK-3 in vitro, although the exact Aβ species and mechanism involved remain unknown (Akiyama et al., 2005; Kim et al., 2003; Ryan and Pimplikar, 2005) . GSK-3α promotes Aβ production (Phiel et al., 2003) and phosphorylates APP and presenilin-1 in vitro (Aplin et al., 1997; Takashima et al., 1998) . In vitro and in vivo GSK-3β overexpression leads to neuronal apoptosis (Beurel and Jope, 2006; Bhat et al., 2000a; Hetman et al., 2000; Kosik, 1992) . GSK-3β also participates in memory and synaptic plasticity, and mice overexpressing GSK-3β showed impaired memory and longterm potentiation (LTP) (Hernandez et al., 2002) . The above evidence has already led to clinical trials of GSK-3 inhibitors in AD, although there are major gaps in knowledge concerning GSK-3 effects in the human brain and uncertainty about whether drugs that specifically target GSK-3 are feasible and safe.
We tested the hypothesis that increased activity of GSK-3β substantially contributes to Aβ-induced neuronal damage in AD. We propose that soluble oligomeric Aβ species trigger GSK-3β activation, and this in turn mediates the AD neurodegenerative phenotype by 
